Our team

Board of Directors

Joanna Shields
Executive Director
François Nader
Chairman
John Orloff
Non-Executive Director
Nigel Shadbolt
Non-Executive Director
Ethan Park
Non-Executive Director
Ken Mulvany
Founder and Board Director
Jackie Hunter
Non-Executive Director
Michael Brennan
Co-Founder, Non-Executive Director

Leadership

Joanna Shields
CEO
Anne Phelan
CSO
Ivan Griffin
COO & Co-Founder
Daniel Neil
CTO
Mark Davies
SVP Informatics and Data
Trecilla Lobo
SVP People
Bryn Williams-Jones
SVP Drug Discovery
Dave Michalovich
SVP Precision Medicine
Nikki Robas
VP Drug Discovery
Ed Savory
VP Drug Discovery
Rosa Vega
VP of Technical Programme Management
Peter Richardson
VP Pharmacology
Peter Cox
VP Drug Discovery
Constantinos Neophytou
VP Engineering
Catherine Tucker
VP Business Development
Will Scrimshaw
General Counsel
Rajin Kang
VP Communications

Scientific Advisors

Russ Altman
Scientific Advisor
Nigel Shadbolt
Scientific Advisor
Jackie Hunter
Scientific Advisor
JB Michel
Scientific Advisor
Justin Stebbing
Scientific Advisor
Lately at Benevolent

Recent updates

News
BenevolentAI Appoints Daniel Neil as Chief Technology Officer
Daniel Neil has been promoted to Chief Technology Officer to develop BenevolentAI’s long term technology strategy for artificial intelligence-driven drug discovery.
Jan 21, 2022
News
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
BenevolentAI and AstraZeneca add systemic lupus erythematosus and heart failure to their expanded AI drug discovery collaboration.
Jan 13, 2022
News
BenevolentAI to Present at the 40th Annual JP Morgan Healthcare Conference
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
Jan 6, 2022
Drug programmesINVESTORSPARTNERINGcareers
Contact us →
Company Registration: 09781806
Terms & Conditions
Privacy & Cookies Policy